A 28-year-old man from Delhi presents with a 6-month history of bloody diarrhea, abdominal pain, and weight loss. Colonoscopy shows continuous mucosal inflammation limited to the colon with crypt abscess formation and surface ulceration. Histology confirms inflammation confined to the mucosa and submucosa. Laboratory tests show elevated ESR and CRP. He has no extraintestinal manifestations. What is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis The patient presents with a classic presentation of **ulcerative colitis (UC)**: - Continuous mucosal inflammation limited to the colon - Crypt abscess and surface ulceration (mucosal/submucosal involvement only) - No skip lesions or transmural disease - First episode of moderate disease (bloody diarrhea, weight loss, elevated inflammatory markers) ## Management Algorithm for UC Induction of Remission ```mermaid flowchart TD A[Confirmed UC diagnosis]:::outcome --> B{Disease severity?}:::decision B -->|Mild-moderate| C[5-ASA compounds]:::action B -->|Severe/fulminant| D[IV corticosteroids]:::action C --> E{Response at 4 weeks?}:::decision E -->|Yes| F[Continue 5-ASA maintenance]:::action E -->|No| G[Add corticosteroids or escalate]:::action D --> H[Assess for colectomy indication]:::decision ``` ## Why 5-ASA Is First-Line for This Patient **Key Point:** 5-ASA (mesalamine) is the first-line induction therapy for mild-to-moderate UC. This patient has: - No signs of severe disease (no fever, no tachycardia, no severe anemia mentioned) - Mucosal-only inflammation (not transmural) - First presentation (steroid-naive) **High-Yield:** Typical dosing for induction: mesalamine 3–4 g/day in divided doses. Efficacy improves with higher doses (≥2 g/day) for induction. **Clinical Pearl:** 5-ASA works topically in the colon and has both anti-inflammatory and immunomodulatory effects. It is superior to placebo and equivalent to corticosteroids for mild-moderate disease. ## Timing of Escalation | Step | Timing | Indication | |------|--------|------------| | 5-ASA monotherapy | Weeks 0–4 | Mild-moderate disease | | Add corticosteroids | Week 4 if no response | Inadequate response to 5-ASA | | Add azathioprine | Week 8–12 if steroid-dependent | Steroid dependence or frequent relapses | | Colectomy | Acute: toxic megacolon, perforation; Chronic: dysplasia, failed medical therapy | Indications for surgery | **Mnemonic:** **ASAP** — **A**minosalicylates, **S**teroids, **A**zathioprine, **P**roactively escalate (in order of first-line use).